Author:
Wenzel Mike,Cano Garcia Cristiana,Humke Clara,Hoeh Benedikt,Steuber Thomas,Tilki Derya,Merseburger Axel S.,Kluth Luis A.,Chun Felix K.H.,Mandel Philipp
Reference29 articles.
1. Mottet N, van den Bergh RCN, Briers E, et al. EAU guidelines on prostate cancer. 2019.
2. Merseburger AS, Chowdhury S, Bahl A. Therapy optimization in the management of metastatic hormone-sensitive prostate cancer: insights from the ARASENS study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.010.
3. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019
4. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer;Armstrong;J Clin Oncol,2019
5. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019